维布妥昔单抗治疗CD30阳性外周T细胞淋巴瘤的研究进展

缪祎; 徐卫; 李建勇

doi:10.12354/j.issn.1000-8179.2022.20211739

维布妥昔单抗治疗CD30阳性外周T细胞淋巴瘤的研究进展

doi: 10.12354/j.issn.1000-8179.2022.20211739

缪祎^1,,
徐卫¹,
李建勇^{1, 2, ,}

1.
南京医科大学第一附属医院江苏省人民医院血液科（南京市210029）
2.
苏州大学第一附属医院，国家血液系统疾病临床医学研究中心

基金项目: 本文课题受国家血液系统疾病临床研究中心转化研究项目（编号：2020ZKZB01）资助

详细信息

作者简介:
缪祎：专业方向为淋巴瘤的诊治与研究。

通讯作者:
李建勇 lijianyonglm@126.com

计量
- 文章访问数: 246
- HTML全文浏览量: 140
- PDF下载量: 51
- 被引次数: 0
出版历程
- 收稿日期: 2021-11-22
- 录用日期: 2022-04-28
- 修回日期: 2022-03-29
- 网络出版日期: 2022-05-30

Research advances of brentuximab vedotin in the treatment of CD30+ peripheral T-cell lymphoma

Yi Miao^1
,,
Wei Xu¹,
Jianyong Li^{1, 2
, ,}

1.
Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2.
The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Soochow 215006, China

Funds: This work was supported by Translational Research Grant of National Clinical Research Center for Hematologic Diseases (No. 2020ZKZB01)

More Information

Corresponding author: Jianyong Li; E-mail: lijianyonglm@126.com

摘要

摘要: 维布妥昔单抗（brentuximab vedotin，BV）是一种新型的靶向抗体-药物偶联物（antibody-drug conjugate，ADC），最早被美国食品药品监督管理局（FDA）批准用于复发难治性霍奇金淋巴瘤（Hodgkin's lymphoma，HL）和系统性间变大细胞淋巴瘤（systemic anaplastic large cell lymphoma ，sALCL）的治疗，2018年11月美国FDA批准BV 联合化疗方案用于初治的CD30+外周T细胞淋巴瘤（peripheral T-cell lymphoma，PTCL）患者。PTCL是一类具有异质性、侵袭性强及恶性程度高和疗效差特点的淋巴系统肿瘤。CD30在PTCL亚型中有不同的表达，检测CD30可以为诊断和治疗决策提供指导。BV在新诊断和复发难治性PTCL患者中均表现出显著的抗肿瘤活性，在sALCL患者中的疗效显著并且持续。BV临床应用的总体耐受良好，临床主要的不良反应是周围神经病变。本文旨在综述BV治疗PTCL的有效性和安全性。
- 外周T细胞淋巴瘤 /
- 维布妥昔单抗 /
- CD30阳性 /
- 周围神经病变
Abstract: Brentuximab vedotin (BV), a novel targeted antibody–drug conjugate (ADC), was first approved by the US Food and Drug Administration for the treatment of relapsed and refractory Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). BV combined with chemotherapy regimen was approved for the treatment of CD30+ peripheral T-cell lymphoma (PTCL) patients in November 2018. PTCL is a type of lymphoid system tumor with characteristics of heterogeneity, strong invasiveness, a high degree of malignancy, and poor curative effect. CD30 is differentially expressed in the PTCL subtypes, and detection of CD30 can provide guidance in diagnosis and treatment decisions. Relevant studies have shown that BV exhibits significant antitumor activity in both newly diagnosed and relapsed and refractory PTCL patients, and the efficacy in systemic anaplastic large cell lymphoma patients was significant and sustained. The clinical application of BV was generally well tolerated, and the main clinical adverse reaction was peripheral neuropathy. This article discusses the efficacy and safety of BV in the treatment of PTCL.
- brentuximab vedotin (BV) /
- peripheral T-cell lymphoma (PTCL) /
- CD30 positive /
- peripheral neuropathy

HTML全文

参考文献(29)

[1]	Sakata-Yanagimoto M, Fukumoto K, Karube K, et al. Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): a complex disease category[J]. J Clin Exp Hematop, 2021, 61(2):61-70. doi: 10.3960/jslrt.20059
[2]	Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study[J]. Blood, 2021, 137(16):2161-2170. doi: 10.1182/blood.2020009004
[3]	Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy[J]. Ann Oncol, 2014, 25(11):2211-2217. doi: 10.1093/annonc/mdu443
[4]	Marchi E, O'Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management[J]. CA Cancer J Clin, 2020, 70(1):47-70. doi: 10.3322/caac.21589
[5]	Xie CQ, Li X, Zeng H, et al. Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma[J]. Exp Hematol Oncol, 2020, 9(1):30. doi: 10.1186/s40164-020-00188-w
[6]	Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study[J]. Blood, 2004, 103(7):2474-2479. doi: 10.1182/blood-2003-09-3080
[7]	Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project[J]. Blood, 2021, 138(3):213-220.
[8]	Nizamuddin I, Galvez C, Pro B. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin[J]. Semin Hematol, 2021, 58(2):85-94. doi: 10.1053/j.seminhematol.2021.02.006
[9]	Bisig B, de Reyniès A, Bonnet C, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features[J]. Haematologica, 2013, 98(8):1250-1258. doi: 10.3324/haematol.2012.081935
[10]	Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels[J]. Blood, 2014, 124(19):2983-2986. doi: 10.1182/blood-2014-07-584953
[11]	Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study[J]. Am J Surg Pathol, 2012, 36(4):481-499. doi: 10.1097/PAS.0b013e31824433d8
[12]	Gammon B, Gammon BR, Kim YH, et al. Neurotropic gamma-delta T-cell lymphoma with CD30-positive lymphoid infiltrates[J]. Am J Dermatopathol, 2016, 38(9):e133-e136. doi: 10.1097/DAD.0000000000000560
[13]	Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation[J]. Am J Surg Pathol, 2011, 35(8):1214-1225. doi: 10.1097/PAS.0b013e31822067d1
[14]	Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas[J]. Haematologica, 2013, 98(8):e81-e82. doi: 10.3324/haematol.2013.084913
[15]	Raghavan SS, Hong EK, Kim YH, et al. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation[J]. J Cutan Pathol, 2019, 46(1):33-43. doi: 10.1111/cup.13375
[16]	Yi JH, Lee GW, Do YR, et al. Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma[J]. Ann Hematol, 2019, 98(11):2541-2550.
[17]	Shi Y, Wang ED. Hepatosplenic T-cell lymphoma: a clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell/natural killer-cell neoplasms[J]. Arch Pathol Lab Med, 2015, 139(9):1173-1180. doi: 10.5858/arpa.2014-0079-RS
[18]	Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas[J]. F1000 Research, 2020, 9:1000-1091.
[19]	Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2
[20]	Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy[J]. Nat Biotechnol, 2003, 21(7):778-784. doi: 10.1038/nbt832
[21]	Munekage E, Serada S, Tsujii S, et al. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma[J]. Neoplasia, 2021, 23(9):939-950. doi: 10.1016/j.neo.2021.07.006
[22]	Okeley NM, Miyamoto JB, Zhang XQ, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate[J]. Clin Cancer Res, 2010, 16(3):888-897. doi: 10.1158/1078-0432.CCR-09-2069
[23]	Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas[J]. N Engl J Med, 2010, 363(19):1812-1821. doi: 10.1056/NEJMoa1002965
[24]	Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study[J]. J Clin Oncol, 2012, 30(18):2190-2196.
[25]	Stefoni V, Corradini P, Orsucci L, et al. Brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T-cell lymphoma patients: a phase 2 study of the fondazione italiana linfomi[J]. Blood, 2020, 136:21.
[26]	Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase Ⅲ study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma[J]. Ann Oncol, 2022, 33(3): 288-298.
[27]	Alex F, Jasmine Z, Kerry J, et al. 133 brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) follow by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas[J]. Ann Meet Exp , 2021, (11):89-96.
[28]	Tournilhac O, Hacini M, Bouabdallah K, et al. Addition of brentuximab vedotin to gemcitabine in relapsed or refractory T-cell lymphoma: results of a lysa multicenter, phase Ⅱ study. “the TOTAL trial”[J]. Blood, 2020, 136:15-16.
[29]	Kanate AS, Kumar A, Dreger P, et al. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the lymphoma working party of EBMT[J]. JAMA Oncol, 2019, 5(5):715-722.